What chemotherapy treatments font perdre les cheveux ?
Not all treatments cause the same hair loss. Update on the families of molecules, their risk of alopecia and the timetable for hair loss.
The risk of alopecia following chemotherapy refers to the probability, which varies depending on the medication, that the treatment will cause hair loss. It depends on the family of molecules, the doses, the rhythm of the treatments and their associations. Some protocols result in near total alopecia, others moderate or rare loss.
Not all chemotherapies cause hair loss in the same way. The agents that most harm rapidly dividing cells—taxanes, anthracyclines, alkylating agents—are the most alopecia-inducing, with incidence rates often exceeding 80% in combination. Conversely, certain antimetabolites and targeted therapies cause more moderate hair loss or simple thinning. To this medication drop can be added a drop linked to the stress of the announcement and the course, by a mechanism of telogen effluvium involving cortisol. The loss generally begins two to three weeks after the first treatment. Only the healthcare team can specify the real risk of a given protocol. This article details the families of treatments, the role of stress and the timing of the fall.
The chemotherapies most likely to cause hair loss are taxanes (docetaxel, paclitaxel), anthracyclines (doxorubicin, epirubicin) and alkylating agents (cyclophosphamide), especially in combination, with an incidence of alopecia that can exceed 80 to 90%. Antimetabolites and many targeted therapies cause a more moderate fall. In addition to this medication drop, there can be a diffuse fall linked to stress (telogen effluvium), even with a low-alopecia protocol. The loss generally begins two to three weeks after the first treatment.
Pourquoi certains traitements cause more falls than others
Alopecia depends on a treatment's ability to affect the rapidly dividing cells of the hair follicle. The more strongly a molecule acts on these cells, the more marked the fall. But the medication is not the only factor: the dose, the rhythm of the treatments and especially the combination of several molecules significantly modify the result.
This is why two people receiving different treatments — or the same treatment at different doses — will not experience the same fall. Poly-chemotherapy, which combines several agents, is generally more alopecic than a single molecule.
- The risk of alopecia depends on the action of the molecule on rapidly dividing cells.
- La dose, le rythme et les associations modulent fortement ce risque.
- Poly-chemotherapy causes more hair loss than a single molecule.
The fall is not always medicated: the role of stress
We spontaneously associate hair loss during cancer with medications alone. This means forgetting another cause, common and underestimated: stress. The announcement of the diagnosis, the anxiety of the journey and the emotional upheaval that accompanies them can, in themselves, weaken the hair.
The mechanism at play is telogen effluvium. Under the effect of an intense physical or psychological shock, an abnormal proportion of hair prematurely switches from the growth phase (anagen) to the resting phase (telogen), which ends with loss. Stress hormones, including cortisol, are involved in this shift. The result is a diffuse fall, which typically occurs a few weeks to a few months after the triggering event.
Concretely, this means that a patient can observe a partial loss even when their protocol is not very alopecian, or even before the start of treatments, simply because of the stress of the announcement. This fall linked to stress is then added, if necessary, to the fall of drug origin. Understanding this double origin avoids attributing everything to the treatment and helps to better interpret what we observe.
This mechanism illuminates an often misunderstood circle: hair loss is one of the most feared effects of chemotherapy, to the point of weighing on the acceptance of treatments — and this apprehension itself feeds stress that can aggravate the fall. We detail the psychological weight of alopecia and data on treatment adherence on the page dedicated to chemotherapy-induced alopecia.
Good news: telogen effluvium is usually reversible once the stressor is mitigated. But it reminds us of the importance of taking care of the capillary area throughout the journey, and not just after treatments.
- The stress of the announcement and the journey can cause a fall, regardless of medication.
- The mechanism is telogen effluvium, in which cortisol is involved.
- A partial loss is possible even with a low-alopecia protocol, or before treatment.
- This stress-related fall is usually reversible.
Les familles de traitements and their risk of alopecia
The main families of chemotherapy can be classified according to their tendency to cause alopecia. The figures below are orders of magnitude taken from the literature: they provide benchmarks, but do not replace the opinion of the healthcare team on a precise protocol.
| Famille de traitement | Examples of molecules | Incidence of alopecia |
|---|---|---|
| Anti-microtubule agents (taxanes) | Docetaxel, paclitaxel | Très élevée (> 80 %) |
| Topoisomerase inhibitors | Doxorubicin, epirubicin | High (60 to 100%) |
| ALKYLATING AGENTS | Cyclophosphamide | Élevée (> 60 %) |
| Antimetabolites | Methotrexate, 5-FU, capecitabine | Moderate (10 to 50%) |
| Targeted therapies and hormone therapy | Diverses | Mild to moderate, often diffuse lightening |
In practice, breast cancer protocols combining an anthracycline and a taxane, or an alkylating agent and a taxane, are among the most alopecia-inducing. Associations can achieve rates of 90 to 100%.
- Trüeb R.M. and works cited in Chemotherapy-induced alopecia management: clinical experience and practical advice (Overall incidence ~65%; >80% with anti-microtubules; 60-100% with topoisomerase inhibitors; >60% with alkylants; 10-50% with antimetabolites).
- Review of the literature on the regimen-specific incidence of induced alopecia (associations reaching 90-100%).
When la chute commence-t-elle ?
Whatever the alopecia treatment, hair loss does not occur from the first infusion. It most often begins two to three weeks after the first treatment, until the effect on the growing follicles is visibly visible.
The pace then varies depending on the protocol: the loss can be gradual, in handfuls when brushing, or faster and more massive. With very alopecia protocols, it is often rapid and complete in a few days to a few weeks.
- The loss generally begins two to three weeks after the first treatment.
- Its pace depends on the protocol: progressive or rapid.
- Very alopecia protocols often lead to rapid and complete hair loss.
The cooling helmet peut-il limiter la chute ?
For certain protocols, the cooling helmet — or hypothermic helmet — can reduce the fall. Its principle: cool the scalp during the infusion to tighten the vessels and limit the exposure of follicles to cytotoxic molecules.
Its effectiveness varies greatly depending on the treatments: it is better established for taxane monotherapies than for combinations. It does not guarantee the preservation of hair and is sometimes accompanied by discomfort linked to the cold. Its indication is discussed with the healthcare team.
Que faire pour anticiper ?
Knowing the risk of alopecia in your protocol allows you to prepare for it rather than suffer it. Some useful points of reference:
- Ask the healthcare team what is expected for the precise protocol: it is the only reliable source for a given situation.
- Anticipate a cut plus courte en amont, pour rendre la transition moins brutale.
- Se renseigner sur les solutions de couverture (scarves, prostheses) without rush.
- Discuss the cooling helmet if the protocol lends itself to it.
- Prepare the regrowth en prenant soin du cuir chevelu, dans la logique « on reconstruit avant de stimuler ».
Frequently asked questions
Will my chemotherapy make me lose my hair?
It depends on the molecules and doses. Taxanes, anthracyclines and alkylating agents are the most alopecic, especially in combination. Antimetabolites and targeted therapies cause a more moderate fall. Only your healthcare team can specify what is expected for your protocol.
La perte de cheveux est-elle toujours totale ?
No. Depending on the treatment, it can be total, partial, or limited to diffuse lightening. Combinations of taxanes and anthracyclines cause the greatest losses.
Quand la chute commence-t-elle ?
Most often two to three weeks after the first treatment, gradually or quickly depending on the protocol.
Does the cooling helmet work for all treatments?
No. Its effectiveness is better established for taxane monotherapies than for combinations, and it does not guarantee hair conservation. Its indication is discussed with the healthcare team.
Do targeted therapies cause hair loss?
They more often cause diffuse lightening or modification of the hair than total loss, but this varies depending on the molecules.
Can you lose your hair due to stress, unrelated to medication?
Yes. The stress of the announcement and the journey can trigger telogen effluvium — a diffuse loss linked to the premature shift of hair into the resting phase, in which cortisol is involved. It can occur even with a low-alopecia protocol, or before the start of treatments, and is generally reversible.
This guide is published by the Laboratoire RENASCOR Paris, a French cosmeceutical laboratory specializing in hair reactivation and reconstruction since 2017, and its founder Stéphane Paulet. Our approach is based on a principle: we rebuild before stimulating. Discover our scientific approach and our sources.
Pour aller plus loin
This page is for information only. It does not replace medical advice and does not constitute an individual promise of results.